<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02669667</url>
  </required_header>
  <id_info>
    <org_study_id>D4361C00002</org_study_id>
    <nct_id>NCT02669667</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of MEDI9314 as Single Ascending Dose in Healthy Subjects</brief_title>
  <official_title>A Phase 1a Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI9314 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1a randomized, blinded, placebo-controlled, single-ascending dose study to
      assess the safety and tolerability of MEDI9314 in healthy adult subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I study to assess the safety, tolerability pharmacokinetics, and
      immunogenicity of MEDI9314 following single dose administration to healthy subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 18, 2016</start_date>
  <completion_date type="Actual">June 12, 2017</completion_date>
  <primary_completion_date type="Actual">November 17, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of MEDI9314 by assessment of vital signs: blood pressure</measure>
    <time_frame>240 days post dose</time_frame>
    <description>To assess systolic and diastolic blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of MEDI9314 by assessment of treatment-emergent adverse events</measure>
    <time_frame>240 days post dose</time_frame>
    <description>To assess the number of treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of MEDI9314 by assessment of vital signs: heart rate</measure>
    <time_frame>240 days post dose</time_frame>
    <description>To assess heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of MEDI9314 by assessment of vital signs: temperature</measure>
    <time_frame>240 days post dose</time_frame>
    <description>To assess temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of MEDI9314 by assessment of treatment-emergent serious adverse events</measure>
    <time_frame>240 days post dose</time_frame>
    <description>To assess the incidence of treatment-emergent serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of MEDI9314 by 12-lead electrocardiogram</measure>
    <time_frame>240 days post dose</time_frame>
    <description>To assess 12-lead electrocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of MEDI9314 by physical examination</measure>
    <time_frame>240 days post dose</time_frame>
    <description>To assess subject through a physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of MEDI9314 by clinical laboratory evaluations: hematology</measure>
    <time_frame>240 days post dose</time_frame>
    <description>To assess hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of MEDI9314 by clinical laboratory evaluations: clinical chemistry</measure>
    <time_frame>240 days post dose</time_frame>
    <description>To assess clinical chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of MEDI9314 by clinical laboratory evaluations: urinalysis</measure>
    <time_frame>240 days post dose</time_frame>
    <description>To assess urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of MEDI9314 by assessment of the administration site for local reactions (for Cohorts 4-5 only)</measure>
    <time_frame>5 days post dose</time_frame>
    <description>To assess and monitor the administration site of MEDI9314 for site reactions including redness, swelling, pain, induration and infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of MEDI9314 by assessment of the administration site for local reactions (for Cohorts 1-3 and the Japanese Cohort only)</measure>
    <time_frame>15 days post dose</time_frame>
    <description>To assess and monitor the administration site of MEDI9314 for site reactions including redness, swelling, pain, induration and infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI9314 by assessment of the area under the concentration-time curve from 0 to infinity (AUC0-inf)</measure>
    <time_frame>240 days post dose</time_frame>
    <description>To characterize the pharmacokinetics of MEDI9314</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate immunogenicity of MEDI9314 by the measurement of anti-drug antibodies</measure>
    <time_frame>240 days post dose</time_frame>
    <description>To characterize the pharmacokinetics of MEDI9314</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI9314 by assessment of the area under the concentration-time curve from 0 to last observation (AUC0-t)</measure>
    <time_frame>240 days post dose</time_frame>
    <description>To characterize the pharmacokinetics of MEDI9314</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI9314 by assessment of the area under the concentration-time curve to last quantifiable time point (AUClast)</measure>
    <time_frame>240 days post dose</time_frame>
    <description>To characterize the pharmacokinetics of MEDI9314</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI9314 by assessment of the maximum observed serum drug concentration (Cmax)</measure>
    <time_frame>240 days post dose</time_frame>
    <description>To characterize the pharmacokinetics of MEDI9314</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI9314 by assessment of the time to maximum observed serum drug concentration (tmax; for Cohorts 1-3 and the Japanese Cohort only)</measure>
    <time_frame>240 days post dose</time_frame>
    <description>To characterize the pharmacokinetics of MEDI9314</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI9314 by assessment of the terminal phase elimination half-life (t1/2)</measure>
    <time_frame>240 days post dose</time_frame>
    <description>To characterize the pharmacokinetics of MEDI9314</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Safety</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of MEDI9314 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of MEDI9314 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of MEDI9314 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of MEDI9314 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of MEDI9314 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of MEDI9314 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI9314</intervention_name>
    <description>single dose of MEDI9314</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Japanese Cohort</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>single dose of placebo</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Japanese Cohort</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent.

          2. Age 18 through 50 years at the time of screening.

          3. Female subjects must be of non-childbearing potential.

          4. Nonsterilized males who are sexually active with a female partner of childbearing
             potential must use condom and spermicide.

          5. Body mass index of 19.0 through 32.0 kg/m2 at screening.

          6. No clinically significant abnormality on the basis of medical/medication history or
             physical examination.

          7. Negative drugs of abuse (DOA).

          8. Able and willing to comply with the requirements of the protocol and complete the
             study until the end of the safety follow up period.

          9. For the Japanese Cohort, both of the subject's parents and both sets of grandparents
             must be Japanese.

        Exclusion Criteria:

          1. Any condition that, in the opinion of the investigator, would interfere with
             evaluation of the investigational product or interpretation of subject safety or study
             results.

          2. Concurrent enrollment in another clinical study involving any treatment.

          3. Individuals who are legally institutionalized.

          4. Receipt of &gt; 2 marketed or investigational biologic agents.

          5. Receipt of an investigational biologic agent within 4 months or 5 half-lives prior to
             screening, whichever is longer.

          6. Receipt of any investigational non biologic agent within 3 months or 5 half lives
             prior to screening, whichever is longer.

          7. Use of any medication (prescription or over the counter, including herbal remedies)
             within 14 days or 5 half lives of Day 1, whichever is longer, unless in the opinion of
             the investigator and medical monitor the medication will not interfere with the study
             procedures or compromise subject safety.

          8. Known history of allergy or reaction to any component of the investigational product
             formulation.

          9. History of anaphylaxis following any biologic therapy.

         10. Any clinically relevant abnormal findings in physical examination ECG, vital signs,
             and laboratory parameters.

         11. Positive tuberculosis (TB) test (QuantiFERONÂ®-TB Gold In-tube).

         12. Positive hepatitis B surface antigen, hepatitis C virus antibody or HIV test at
             screening.

         13. Receipt of live attenuated vaccines 30 days prior to the date of screening.

         14. Where donation of blood or blood products was in excess of 500 mL within an 8-week
             period in the 3 months prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muna Albayaty, MBChB, FFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hakop Gevorkyan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2016</study_first_submitted>
  <study_first_submitted_qc>January 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MEDI9314</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Immunogenicity</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

